Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Placebo-Controlled Trial of Urolithin A Supplementation in Men With Prostate Cancer Undergoing Radical Prostatectomy

NCT06022822 is registered in ClinicalTrials.gov with National Cancer Institute (NCI) as lead sponsor.

NCT NCT06022822
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06022822 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Placebo-Controlled Trial of Urolithin A Supplementation in Men With Prostate Cancer Undergoing Radical Prostatectomy
Lead sponsor
National Cancer Institute (NCI)
Phase
Phase 2
Overall status
Recruiting
Start date
September 12, 2024
Completion date
May 1, 2027
Enrollment
90 (estimated)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

prostate adenocarcinoma